Steven Shallcross News Today

Theriva Biologics (TOVX) announced the FDA has granted Fast Track Designation to lead clinical candidate VCN-01 in combination with gemcitabine and nab-paclitaxel to improve progression-free survival and overall survival in patients with metastatic pancreatic adenocarcinoma.

Theriva Biologics, Inc. beats earnings expectations. Reported EPS is $-0.34, expectations were $-0.41. Theriva Biologics, Inc.

Operator: Ladies and gentlemen, good morning, and welcome to the Theriva Biologics, Inc. 2023 Second Quarter Earnings Conference Call.

Theriva Biologics (NYSE:NYSE:TOVX) Q3 2022 Earnings Conference Call November 10, 2022 08:30 ET Company Participants Chris Calabrese - Investor Relations Steven Shallcross - Chief Executive...

FORT PIERCE, FL / ACCESSWIRE / July 7, 2022 / Twin Vee PowerCats Co. (Nasdaq:VEEE) ("Twin Vee" or the "Company"), a designer, manufacturer, distributor, and marketer of power sport catamaran boats, today

07.07.2022 - FORT PIERCE, FL / ACCESSWIRE / July 7, 2022 / Twin Vee PowerCats Co. (Nasdaq:VEEE) (Twin Vee or the Company), a designer, manufacturer, distributor, and marketer of power sport catamaran boats, today announced that Kevin Schuyler was appointed ... Seite 1

Synthetic Biologics, Inc. (NYSE:NYSE:SYN) Q1 2022 Earnings Conference Call May 16, 2022, 09:00 AM ET Company Participants Dean Schwartz - LifeSci Advisors, IR Steven Shallcross - CEO and...

/PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in...

/PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in...

/PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in...